Cargando…

Mesoporous Silica Nanoparticles: Properties and Strategies for Enhancing Clinical Effect

Due to the theragnostic potential of mesoporous silica nanoparticles (MSNs), these were extensively investigated as a novel approach to improve clinical outcomes. Boasting an impressive array of formulations and modifications, MSNs demonstrate significant in vivo efficacy when used to identify or tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Frickenstein, Alex N., Hagood, Jordan M., Britten, Collin N., Abbott, Brandon S., McNally, Molly W., Vopat, Catherine A., Patterson, Eian G., MacCuaig, William M., Jain, Ajay, Walters, Keisha B., McNally, Lacey R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072651/
https://www.ncbi.nlm.nih.gov/pubmed/33920503
http://dx.doi.org/10.3390/pharmaceutics13040570
_version_ 1783683956144603136
author Frickenstein, Alex N.
Hagood, Jordan M.
Britten, Collin N.
Abbott, Brandon S.
McNally, Molly W.
Vopat, Catherine A.
Patterson, Eian G.
MacCuaig, William M.
Jain, Ajay
Walters, Keisha B.
McNally, Lacey R.
author_facet Frickenstein, Alex N.
Hagood, Jordan M.
Britten, Collin N.
Abbott, Brandon S.
McNally, Molly W.
Vopat, Catherine A.
Patterson, Eian G.
MacCuaig, William M.
Jain, Ajay
Walters, Keisha B.
McNally, Lacey R.
author_sort Frickenstein, Alex N.
collection PubMed
description Due to the theragnostic potential of mesoporous silica nanoparticles (MSNs), these were extensively investigated as a novel approach to improve clinical outcomes. Boasting an impressive array of formulations and modifications, MSNs demonstrate significant in vivo efficacy when used to identify or treat myriad malignant diseases in preclinical models. As MSNs continue transitioning into clinical trials, a thorough understanding of the characteristics of effective MSNs is necessary. This review highlights recent discoveries and advances in MSN understanding and technology. Specific focus is given to cancer theragnostic approaches using MSNs. Characteristics of MSNs such as size, shape, and surface properties are discussed in relation to effective nanomedicine practice and projected clinical efficacy. Additionally, tumor-targeting options used with MSNs are presented with extensive discussion on active-targeting molecules. Methods for decreasing MSN toxicity, improving site-specific delivery, and controlling release of loaded molecules are further explained. Challenges facing the field and translation to clinical environments are presented alongside potential avenues for continuing investigations.
format Online
Article
Text
id pubmed-8072651
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80726512021-04-27 Mesoporous Silica Nanoparticles: Properties and Strategies for Enhancing Clinical Effect Frickenstein, Alex N. Hagood, Jordan M. Britten, Collin N. Abbott, Brandon S. McNally, Molly W. Vopat, Catherine A. Patterson, Eian G. MacCuaig, William M. Jain, Ajay Walters, Keisha B. McNally, Lacey R. Pharmaceutics Review Due to the theragnostic potential of mesoporous silica nanoparticles (MSNs), these were extensively investigated as a novel approach to improve clinical outcomes. Boasting an impressive array of formulations and modifications, MSNs demonstrate significant in vivo efficacy when used to identify or treat myriad malignant diseases in preclinical models. As MSNs continue transitioning into clinical trials, a thorough understanding of the characteristics of effective MSNs is necessary. This review highlights recent discoveries and advances in MSN understanding and technology. Specific focus is given to cancer theragnostic approaches using MSNs. Characteristics of MSNs such as size, shape, and surface properties are discussed in relation to effective nanomedicine practice and projected clinical efficacy. Additionally, tumor-targeting options used with MSNs are presented with extensive discussion on active-targeting molecules. Methods for decreasing MSN toxicity, improving site-specific delivery, and controlling release of loaded molecules are further explained. Challenges facing the field and translation to clinical environments are presented alongside potential avenues for continuing investigations. MDPI 2021-04-17 /pmc/articles/PMC8072651/ /pubmed/33920503 http://dx.doi.org/10.3390/pharmaceutics13040570 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Frickenstein, Alex N.
Hagood, Jordan M.
Britten, Collin N.
Abbott, Brandon S.
McNally, Molly W.
Vopat, Catherine A.
Patterson, Eian G.
MacCuaig, William M.
Jain, Ajay
Walters, Keisha B.
McNally, Lacey R.
Mesoporous Silica Nanoparticles: Properties and Strategies for Enhancing Clinical Effect
title Mesoporous Silica Nanoparticles: Properties and Strategies for Enhancing Clinical Effect
title_full Mesoporous Silica Nanoparticles: Properties and Strategies for Enhancing Clinical Effect
title_fullStr Mesoporous Silica Nanoparticles: Properties and Strategies for Enhancing Clinical Effect
title_full_unstemmed Mesoporous Silica Nanoparticles: Properties and Strategies for Enhancing Clinical Effect
title_short Mesoporous Silica Nanoparticles: Properties and Strategies for Enhancing Clinical Effect
title_sort mesoporous silica nanoparticles: properties and strategies for enhancing clinical effect
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072651/
https://www.ncbi.nlm.nih.gov/pubmed/33920503
http://dx.doi.org/10.3390/pharmaceutics13040570
work_keys_str_mv AT frickensteinalexn mesoporoussilicananoparticlespropertiesandstrategiesforenhancingclinicaleffect
AT hagoodjordanm mesoporoussilicananoparticlespropertiesandstrategiesforenhancingclinicaleffect
AT brittencollinn mesoporoussilicananoparticlespropertiesandstrategiesforenhancingclinicaleffect
AT abbottbrandons mesoporoussilicananoparticlespropertiesandstrategiesforenhancingclinicaleffect
AT mcnallymollyw mesoporoussilicananoparticlespropertiesandstrategiesforenhancingclinicaleffect
AT vopatcatherinea mesoporoussilicananoparticlespropertiesandstrategiesforenhancingclinicaleffect
AT pattersoneiang mesoporoussilicananoparticlespropertiesandstrategiesforenhancingclinicaleffect
AT maccuaigwilliamm mesoporoussilicananoparticlespropertiesandstrategiesforenhancingclinicaleffect
AT jainajay mesoporoussilicananoparticlespropertiesandstrategiesforenhancingclinicaleffect
AT walterskeishab mesoporoussilicananoparticlespropertiesandstrategiesforenhancingclinicaleffect
AT mcnallylaceyr mesoporoussilicananoparticlespropertiesandstrategiesforenhancingclinicaleffect